A more objective method for determining disease activity is the measurement of MRI parameters, e.g. CNS atrophy measures or T1 gadolinium enhancing or the appearance of new T2 lesions.[3], [35], [36] However, using these methods it is still extremely difficult to precisely define the state of responsiveness after a short period of treatment or preferably before start of the treatment.
Methodological considerations from this study include the measures used to define disability; the responsiveness of the two tools is not addressed, neither tool is validated in the ICU, and the pre- and post-disability measures were different.
What defines the final responsiveness of the system is the amount of DOAs associated with a new track such that it can be labeled confirmed (n doa).
The ER and PR play central roles in defining the hormone responsiveness and therefore in the selection of patients for endocrine therapy.
2 The objectives of this study were to (1) confirm reliability and validity, (2) evaluate the responsiveness, (3) define the threshold for the responders and also the minimal important difference (MID) of the final SOBDA questionnaire in patients with COPD.
Molecular measures are needed that define the quantity and quality of responsiveness to adjust the dosage or change the drug.
Whereas Zhang et al. [ 44] used this model to assess contact sensitivity, we sought to define the kinetics of VEGF-dependent responsiveness in a full-thickness wound grafted with Integra® to determine its correlation with the vascular remodeling seen in our injury model [ 21, 22].
In general, the threshold to define fluid responsiveness with the passive leg raising test is a 10% increase in stroke volume and/or cardiac output.
The threshold to define fluid responsiveness depends on the change in cardiac preload induced by the test (e.g. 15% for fluid challenge, 10% for the PLR test, 5% for the end-expiratory occlusion test).
We defined the terms to evaluate the responsiveness to steroid pulse therapies in the acute phase (before other treatments; eg, plasma exchange, fingolimod); 'complete' meant recovery to the patients' original visual acuities, 'good' meant recovery to more than half of their original visual acuities, 'not good' meant less than 'good' within 1 5 courses of mPSL pulse therapies.
